Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study Assessing the Incidence of Cardiac and Pulmonary Adverse Events (CAEs and PAEs) of Carfilzomib Treatment and the Risk Factors Associated with these Adverse Events in Patients with Plasma Cell Myeloma using the SEER-Medicare Database

Next Previous
Trial Profile

A Study Assessing the Incidence of Cardiac and Pulmonary Adverse Events (CAEs and PAEs) of Carfilzomib Treatment and the Risk Factors Associated with these Adverse Events in Patients with Plasma Cell Myeloma using the SEER-Medicare Database

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions

    • Most Recent Events

    • 13 Nov 2019 Results assessing cardiac adverse events (CAEs) and pulmonary adverse events (PAEs) associated with carfilzomib in patients with multiple myeloma were published in the Cancer
    • 28 Dec 2017 New trial record
    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top